Overview

Creon After Pancreatic Surgery

Status:
Completed

Trial end date:
2011-06-01

Target enrollment:

Participant gender:

Summary

This study will provide efficacy data for Creon 25000 MMS in PS patients as well as long-term safety data. During the long-term treatment with Creon 25000 nutritional parameters will be assessed and correlated with CFA

Phase:

Phase 4

Details

Lead Sponsor:

Abbott Products

Collaborators:

Data Map GmbH
Quintiles, Inc.

Treatments:

Pancreatin
Pancrelipase